Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2009

Open Access 01-12-2009 | Research

Upregulation of CENP-H in tongue cancer correlates with poor prognosis and progression

Authors: Wen-Ting Liao, Chun-Ping Yu, Dong-Hui Wu, Ling Zhang, Li-Hua Xu, Gui-Xiang Weng, Mu-Sheng Zeng, Li-Bing Song, Jin-Song Li

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2009

Login to get access

Abstract

Background

Centromere protein H (CENP-H) is one of the fundamental components of the human active kinetochore. Recently, CENP-H was identified to be associated with tumorigenesis. This study was aimed to investigate the clinicopathologic significance of CENP-H in tongue cancer.

Methods

RT-PCR, real time RT-PCR and Western blot were used to examine the expression of CENP-H in tongue cancer cell lines and biopsies. CENP-H protein level in paraffin-embedded tongue cancer tissues were tested by immunohistochemical staining and undergone statistical analysis. CENP-H-knockdown stable cell line was established by infecting cells with a retroviral vector pSuper-retro-CENP-H-siRNA. The biological function of CENP-H was tested by MTT assay, colony formation assay, and Bromodeoxyuridine (BrdU) incorporation assay.

Results

CENP-H expression was higher in tongue cancer cell lines and cancer tissues (T) than that in normal cell and adjacent noncancerous tongue tissues (N), respectively. It was overexpressed in 55.95% (94/168) of the paraffin-embedded tongue cancer tissues, and there was a strong correlation between CENP-H expression and clinical stage, as well as T classification. CENP-H can predict the prognosis of tongue cancer patients especially those in early stage. Depletion of CENP-H can inhibit the proliferation of tongue cancer cells (Tca8113) and downregulate the expression of Survivin.

Conclusion

These findings suggested that CENP-H involves in the development and progression of tongue cancer. CENP-H might be a valuable prognostic indicator for tongue cancer patients within early stage.
Appendix
Available only for authorised users
Literature
1.
Fukagawa T: Assembly of kinetochores in vertebrate cells. Exp Cell Res. 2004, 296: 21-27. 10.1016/j.yexcr.2004.03.004.CrossRef
2.
Cleveland DW, Mao Y, Sullivan KF: Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell. 2003, 112: 407-421. 10.1016/S0092-8674(03)00115-6.CrossRef
3.
Westermann S, Cheeseman IM, Anderson S, Yates JR, Drubin DG, Barnes G: Architecture of the budding yeast kinetochore reveals a conserved molecular core. J Cell Biol. 2003, 163: 215-222. 10.1083/jcb.200305100.CrossRef
4.
Cheeseman IM, Drubin DG, Barnes G: Simple centromere, complex kinetochore: linking spindle microtubules and centromeric DNA in budding yeast. J Cell Biol. 2002, 157: 199-203. 10.1083/jcb.200201052.CrossRef
5.
De Wulf P, McAinsh AD, Sorger PK: Hierarchical assembly of the budding yeast kinetochore from multiple subcomplexes. Genes Dev. 2003, 17: 2902-2921. 10.1101/gad.1144403.CrossRef
6.
Tomonaga T, Matsushita K, Ishibashi M, Nezu M, Shimada H, Ochiai T, Yoda K, Nomura F: Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. Cancer Res. 2005, 65: 4683-4689. 10.1158/0008-5472.CAN-04-3613.CrossRef
7.
Barbanis S, Ioannou M, Kouvaras E, Karasavvidou F, Nakou M, Papamichali R, Koukoulis G: INCENP (Inner Centromere Protein) is Overexpressed in High Grade Non-Hodgkin B-cell Lymphomas. Pathol Oncol Res. 2009, 15: 11-17. 10.1007/s12253-008-9094-0.CrossRef
8.
Erlanson M, Casiano CA, Tan EM, Lindh J, Roos G, Landberg G: Immunohistochemical analysis of the proliferation associated nuclear antigen CENP-F in non-Hodgkin's lymphoma. Mod Pathol. 1999, 12: 69-74.
9.
Shigeishi H, Mizuta K, Higashikawa K, Yoneda S, Ono S, Kamata N: Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. Oral Oncol. 2005, 41: 716-722. 10.1016/j.oraloncology.2005.03.008.CrossRef
10.
Sugata N, Munekata E, Todokoro K: Characterization of a novel kinetochore protein, CENP-H. J Biol Chem. 1999, 274: 27343-27346. 10.1074/jbc.274.39.27343.CrossRef
11.
Fukagawa T, Mikami Y, Nishihashi A, Regnier V, Haraguchi T, Hiraoka Y, Sugata N, Todokoro K, Brown W, Ikemura T: CENP-H, a constitutive centromere component, is required for centromere targeting of CENP-C in vertebrate cells. Embo J. 2001, 20: 4603-4617. 10.1093/emboj/20.16.4603.CrossRef
12.
Sugata N, Li S, Earnshaw WC, Yen TJ, Yoda K, Masumoto H, Munekata E, Warburton PE, Todokoro K: Human CENP-H multimers colocalize with CENP-A and CENP-C at active centromere – kinetochore complexes. Hum Mol Genet. 2000, 9: 2919-2926. 10.1093/hmg/9.19.2919.CrossRef
13.
Cheeseman IM, Hori T, Fukagawa T, Desai A: KNL1 and the CENP-H/I/K Complex Coordinately Direct Kinetochore Assembly in Vertebrates. Mol Biol Cell. 2008, 19: 587-594. 10.1091/mbc.E07-10-1051.CrossRef
14.
Hori T, Okada M, Maenaka K, Fukagawa T: CENP-O class proteins form a stable complex and are required for proper kinetochore function. Mol Biol Cell. 2008, 19: 843-854. 10.1091/mbc.E07-06-0556.CrossRef
15.
Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM, Li MZ, Qin HD, Zeng YX, Zeng MS: Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res. 2007, 13: 508-514. 10.1158/1078-0432.CCR-06-1512.CrossRef
16.
Guo XZ, Zhang G, Wang JY, Liu WL, Wang F, Dong JQ, Xu LH, Cao JY, Song LB, Zeng MS: Prognostic relevance of Centromere protein H expression in esophageal carcinoma. BMC Cancer. 2008, 8: 233-10.1186/1471-2407-8-233.CrossRef
17.
Shigeishi H, Higashikawa K, Ono S, Mizuta K, Ninomiya Y, Yoneda S, Taki M, Kamata N: Increased expression of CENP-H gene in human oral squamous cell carcinomas harboring high-proliferative activity. Oncol Rep. 2006, 16: 1071-1075.
18.
Reshmi SC, Gollin SM: Chromosomal instability in oral cancer cells. J Dent Res. 2005, 84: 107-117. 10.1177/154405910508400203.CrossRef
19.
Greenberg JS, Fowler R, Gomez J, Mo V, Roberts D, El Naggar AK, Myers JN: Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer. 2003, 97: 1464-1470. 10.1002/cncr.11202.CrossRef
20.
Haddadin KJ, Soutar DS, Webster MH, Robertson AG, Oliver RJ, MacDonald DG: Natural history and patterns of recurrence of tongue tumours. Br J Plast Surg. 2000, 53: 279-285. 10.1054/bjps.1999.1111.CrossRef
21.
Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66: 6225-6232. 10.1158/0008-5472.CAN-06-0094.CrossRef
22.
Patel SG, Shah JP: TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin. 2005, 55: 242-258. 10.3322/canjclin.55.4.242.CrossRef
23.
O'Sullivan B, Shah J: New TNM staging criteria for head and neck tumors. Semin Surg Oncol. 2003, 21: 30-42. 10.1002/ssu.10019.CrossRef
24.
Liao WT, Wang X, Xu LH, Kong QL, Yu CP, Li MZ, Shi L, Zeng MS, Song LB: Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer. 2009, 115: 1507-1017. 10.1002/cncr.24128.CrossRef
25.
Jane C, Nerurkar AV, Shirsat NV, Deshpande RB, Amrapurkar AD, Karjodkar FR: Increased survivin expression in high-grade oral squamous cell carcinoma: a study in Indian tobacco chewers. J Oral Pathol Med. 2006, 35: 595-601. 10.1111/j.1600-0714.2006.00473.x.CrossRef
26.
Kops GJ, Weaver BA, Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005, 5: 773-785. 10.1038/nrc1714.CrossRef
27.
de la Guardia C, Casiano CA, Trinidad-Pinedo J, Baez A: CENP-F gene amplification and overexpression in head and neck squamous cell carcinomas. Head Neck. 2001, 23: 104-112. 10.1002/1097-0347(200102)23:2<104::AID-HED1005>3.0.CO;2-0.CrossRef
28.
Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH: Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997, 57: 5505-5508.
29.
Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP: Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci. 2003, 116: 2987-2998. 10.1242/jcs.00612.CrossRef
30.
Lens SM, Vader G, Medema RH: The case for Survivin as mitotic regulator. Curr Opin Cell Biol. 2006, 18: 616-622. 10.1016/j.ceb.2006.08.016.CrossRef
31.
Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003, 22: 8581-8589. 10.1038/sj.onc.1207113.CrossRef
32.
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998, 396: 580-584. 10.1038/25141.CrossRef
33.
Lo Muzio L, Farina A, Rubini C, Pezzetti F, Stabellini G, Laino G, Santarelli A, Pannone G, Bufo P, de Lillo A, Carinci F: Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett. 2005, 225: 27-33. 10.1016/j.canlet.2004.11.024.CrossRef
34.
Lo Muzio L, Pannone G, Leonardi R, Staibano S, Mignogna MD, De Rosa G, Kudo Y, Takata T, Altieri DC: Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res. 2003, 82: 923-928. 10.1177/154405910308201115.CrossRef
Metadata
Title
Upregulation of CENP-H in tongue cancer correlates with poor prognosis and progression
Authors
Wen-Ting Liao
Chun-Ping Yu
Dong-Hui Wu
Ling Zhang
Li-Hua Xu
Gui-Xiang Weng
Mu-Sheng Zeng
Li-Bing Song
Jin-Song Li
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2009
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-28-74

Other articles of this Issue 1/2009

Journal of Experimental & Clinical Cancer Research 1/2009 Go to the issue

Research

Evaluation of skin dose associated with different frequencies of bolus applications in post-mastectomy three-dimensional conformal radiotherapy

Case report

Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports

Research

Subcellular localization of APMCF1 and its biological significance of expression pattern in normal and malignant human tissues

Research

Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo

Research

Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells

Research

Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits